Simulations Plus, Inc. $SLP Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. lowered its position in Simulations Plus, Inc. (NASDAQ:SLP) by 65.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 49,335 shares of the technology company’s stock after selling 94,294 shares during the quarter. Goldman Sachs Group Inc. owned approximately 0.25% of Simulations Plus worth $1,210,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SLP. Fifth Third Bancorp lifted its stake in Simulations Plus by 33.8% in the first quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company’s stock valued at $36,000 after buying an additional 375 shares during the last quarter. US Bancorp DE raised its stake in shares of Simulations Plus by 15.6% during the first quarter. US Bancorp DE now owns 6,576 shares of the technology company’s stock worth $161,000 after purchasing an additional 889 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Simulations Plus during the first quarter worth approximately $210,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Simulations Plus by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after purchasing an additional 390 shares during the last quarter. Finally, Savvy Advisors Inc. purchased a new stake in shares of Simulations Plus during the first quarter worth approximately $249,000. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Simulations Plus Stock Performance

Simulations Plus stock opened at $15.25 on Monday. The firm has a market capitalization of $306.98 million, a price-to-earnings ratio of -4.84 and a beta of 0.85. Simulations Plus, Inc. has a fifty-two week low of $12.39 and a fifty-two week high of $37.67. The stock’s fifty day moving average is $13.99 and its two-hundred day moving average is $22.15.

Simulations Plus (NASDAQ:SLP) last posted its earnings results on Monday, July 14th. The technology company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.26 by $0.19. The company had revenue of $20.36 million for the quarter, compared to analyst estimates of $22.83 million. Simulations Plus had a positive return on equity of 11.62% and a negative net margin of 78.63%.Simulations Plus’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.27 earnings per share. As a group, sell-side analysts forecast that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. BTIG Research cut their price target on Simulations Plus from $41.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, July 7th. Stephens cut their price target on Simulations Plus from $28.00 to $20.00 and set an “overweight” rating for the company in a research note on Tuesday, July 15th. KeyCorp cut Simulations Plus from an “overweight” rating to a “sector weight” rating in a research note on Tuesday, July 15th. JMP Securities reaffirmed a “market perform” rating on shares of Simulations Plus in a report on Wednesday, June 18th. Finally, William Blair reaffirmed an “outperform” rating on shares of Simulations Plus in a report on Tuesday, July 15th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Simulations Plus currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.50.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.